Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in St. Ingbert – page 23

306 clinical trials in St. Ingbert, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
St. Ingbert at a glance
306
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

306 trials in St. Ingbert

Open in trial search

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+2

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study on Regorafenib and Pembrolizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Translational Research In Oncology

Glioblastoma

Not recruiting

Study on Perampanel Treatment Before Surgery for Patients with Progressive Glioblastoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Perampanel
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in St. Ingbert

What the registry says about research in the country

01 Cardiovascular Diseases

In St. Ingbert-Oberwürzbach, clinical research in cardiovascular diseases is focused on reducing heart-related risk and improving long-term outcomes for people with atherosclerotic cardiovascular disease and broader cardiovascular disease concerns.

  • Studies on protecting against major cardiovascular events such as heart attack and stroke
  • Research evaluating whether new treatments can lower cardiovascular risk alongside standard care
  • Trials examining cholesterol control in people with established heart and blood vessel disease

These trials aim to test whether newer therapies can improve prevention and treatment effectiveness in everyday care.

02 Nutritional and Metabolic Diseases

A second major research area is nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes.

  • Weight management studies for people living with obesity or excess body weight
  • Trials combining diabetes care with efforts to support healthier weight outcomes
  • Research looking at better approaches for long-term metabolic control

The overall goal is to explore treatments that can help people lose weight, maintain results, and reduce related health risks.

03 Diabetes and Glycaemic Control

Several studies are centered on diabetes, including type 1 diabetes and type 2 diabetes mellitus, with attention to improving blood sugar control and related complications.

  • Trials comparing new insulin strategies for people with type 1 diabetes
  • Research on glucose-lowering treatments for patients with type 2 diabetes and cardiovascular risk
  • Studies assessing the broader impact of diabetes therapies on long-term health

This work is designed to see whether newer treatment approaches can offer better control and support safer diabetes management.

04 Obesity and Weight Management

A large share of the local trial activity involves obesity and chronic weight management, reflecting strong interest in therapies that support meaningful and lasting weight reduction.

  • Studies testing new medicines for adults with obesity or overweight
  • Research focused on maintaining weight loss over time
  • Trials examining how weight reduction may also improve related metabolic health

These studies are intended to better understand how treatment can support healthier body weight and reduce associated complications.

05 Lipid Lowering and Cardiometabolic Risk

Some trials in Germany are investigating whether newer lipid-lowering approaches can better manage hypercholesterolemia and lower the risk of future heart problems.

  • Research comparing cholesterol-lowering options in people with cardiovascular disease
  • Studies assessing added benefit alongside standard treatment
  • Trials aimed at improving prevention of heart and vascular events

The focus is on finding more effective ways to reduce harmful cholesterol and protect long-term cardiovascular health.

06 Eye Health in Diabetes

One notable study area examines diabetic retinopathy in people with type 2 diabetes, exploring whether diabetes treatment can influence eye health over time.

  • Safety-focused research on long-term effects for diabetic eye disease
  • Studies using ophthalmic assessments to monitor progression
  • Work aimed at understanding how improved glucose control may affect eye complications

This research supports a better understanding of how diabetes therapies may shape both blood sugar control and vision-related outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.